Article
The effect of mild and moderate hepatic impairment on the pharmacokinetics of tofacitinib, an orally active Janus kinase inhibitor.
Clinical pharmacology in drug development - 1 Nov 2014
Lawendy Nervin, Lamba Manisha, Chan Gary, Wang Rong, Alvey Christine W, Krishnaswami Sriram
Abstract excerpt
Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. We report here an evaluation of the pharmacokinetics of a single 10 mg dose of tofacitinib in healthy volunteers (n = 6) and subjects with mild (n = 6) or moderate (n = 6) hepatic impairment. Compared to healthy volunteers, tofacitinib area under the plasma concentration-time profile from time 0 to infinity (AUCinf ) and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.